These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 469238)

  • 21. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
    Moriniere P; Roussel A; Tahiri Y; de Fremont JF; Maurel G; Jaudon MC; Gueris J; Fournier A
    Proc Eur Dial Transplant Assoc; 1983; 19():784-7. PubMed ID: 6878265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational nursing care in chronic renal disease.
    Lavandero R; Davis V
    Am J Nurs; 1979 Nov; 79(11):1938, 1941. PubMed ID: 258954
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of different doses of aluminium hydroxide on renal deterioration and nutritional state in experimental chronic renal failure.
    Sanai T; Okuda S; Onoyama K; Motomura K; Osato S; Hori K; Iseki K; Fujishima M
    Miner Electrolyte Metab; 1991; 17(3):160-5. PubMed ID: 1779937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

  • 25. [Features of correction of phosphate-calcium metabolism disorders in terminal renal failure].
    Pilotovich VS; Romanovich VP; Shilaĭ LM; Tukaĭ NN
    Klin Med (Mosk); 1992; 70(3-4):49-51. PubMed ID: 1507848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    Wheeler DC; Smith B; Walls J
    Lancet; 1986 Jun; 1(8494):1380. PubMed ID: 2872489
    [No Abstract]   [Full Text] [Related]  

  • 27. [Magnesium hydroxide treatment of hyperphosphatemia in chronic hemodialysis patients with an aluminum overload].
    Roujouleh H; Lavaud S; Toupance O; Melin JP; Chanard J
    Nephrologie; 1987; 8(2):45-50. PubMed ID: 3614505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model.
    Terai K; Mizukami K; Okada M
    Nephrology (Carlton); 2008 Apr; 13(2):139-46. PubMed ID: 18275502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum-aluminum in nondialyzed chronic uremic patients before and during treatment with aluminum-containing phosphate-binding gels.
    Brahm M
    Clin Nephrol; 1986 May; 25(5):231-5. PubMed ID: 3720033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aluminum poisoning by phosphate binders in kidney insufficiency].
    Fuchs C; Dorn D; Doht B; Freytag E; Fuchs CA; Henning HV; Scheler F
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1313-5. PubMed ID: 611842
    [No Abstract]   [Full Text] [Related]  

  • 32. Aluminium hydroxide and cholestyramine in the treatment of acute diarrhea.
    Pichaipat V; Pinyosamosorn R; Varavithya W
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():155-8. PubMed ID: 2659716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Spontaneous colon perforation in patients with chronic kidney failure].
    Nöthiger F; Oesch I; Blumberg A
    Helv Chir Acta; 1978 May; 45(1-2):93-5. PubMed ID: 659254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pseudo-porphyria cutanea tarda in patients with chronic renal insufficiency and in patients with renal transplants].
    Antonello A; Peserico A; Corsano A; Zannini G; Fagiolo U
    Minerva Chir; 1980 May; 35(10):775-7. PubMed ID: 7005735
    [No Abstract]   [Full Text] [Related]  

  • 36. Citric acid in calcium effervescent tablets may favour aluminium intoxication.
    Dorhout Mees EJ; Basçi A
    Nephron; 1991; 59(2):322. PubMed ID: 1956499
    [No Abstract]   [Full Text] [Related]  

  • 37. Aluminium retention and toxicity in chronic renal failure.
    Thurston H; Gilmore GR; Swales JD
    Lancet; 1972 Apr; 1(7756):881-3. PubMed ID: 4111831
    [No Abstract]   [Full Text] [Related]  

  • 38. Bowel obstruction occurring in a child during treatment with aluminum hydroxide gel.
    Hurley JK
    J Pediatr; 1978 Apr; 92(4):592-3. PubMed ID: 633020
    [No Abstract]   [Full Text] [Related]  

  • 39. Aluminium and chronic renal failure.
    Thurston H; Swales JD
    Br Med J; 1971 Nov; 4(5785):490. PubMed ID: 5125296
    [No Abstract]   [Full Text] [Related]  

  • 40. Ranitidine reduces aluminium toxicity in patients with renal failure.
    Czapla K; Rodger RS; Halls DJ; Muralikrishna GS; Macdougall AI; Fell GS
    Nephrol Dial Transplant; 1992; 7(12):1246-8. PubMed ID: 1337167
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.